The Rising Prevalence of Infections to Boost the Growth of Antiviral Drugs Market


Antiviral Drugs Market, by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors and Others), by Type (Branded and Generics), by Application (HIV, Hepatitis, Herpes, Influenza, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028

The global Antiviral Drugs Market is estimated to be valued at US$ XX million in XXX and is expected to exhibit a CAGR of XX% over the forecast period, as highlighted in a new report published by Coherent Market Insights. Antiviral drugs are a kind of drugs that aid the body fight against some viruses that can lead to disease. Antiviral drugs are also inhibitive. They can save one from being infected virally or spreading the virus to others.

The global Antiviral Drugs Market is estimated to be valued at US$ 56,480.7 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028).

Competitive Landscape:

Key players involved in the global antiviral drugs market are Aurobindo Pharma, F. Hoffmann-La Roche AG, GlaxoSmithKline plc. AbbVie Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Dr. Reddy's Laboratories Ltd., Cipla Inc., and Gilead Sciences.

Market Key Drivers:

The rising prevalence of infections such as HIV and influenza is expected to augment the growth of global market. For instance, as per UNAIDS, above 37 million people globally were affected with HIV globally in 2020.

The rising cases of hepatitis is projected to propel the growth of global market. For instance, as per WHO, 325 million people are suffering from hepatitis globally in 2020.

Covid-19 Impact Analysis:

The COVID-19 pandemic has adversely affected the need for antiviral drugs globally. The therapy of novel coronavirus has expanded the need for broad-spectrum antiviral drugs to control the disorder. Remdesivir, oseltamivir, and other combination drugs are heavily suggested for the therapy of COVID-19.

Key Takeaways:

The global market is anticipated to exhibit a CAGR of XX % during the forecast period owing to rising approval and anticipated commercialization of new drugs for viral infections. For instance, in November 2020, the U.S. FDA has granted a substitute novel Drug Application for Roche’s Xofluza for the therapy of influenza in individuals aged 12 years and above.

Among regions, North America, Europe and Asia Pacific are expected to witness robust growth in global market due to rising cases of hepatitis, HIV and rising regulatory initiatives. For instance, the U.S. regulatory is undertaking several measures consisting expenditure in infectious disorder programs and increasing the Research & Development activities of development treatments to control viral infections.

Comments

Popular posts from this blog

Agricultural Micronutrients Market Growth Accelerated By Increasing Need For Improved Soil Fertility

Dairy Alternative Market Expected To Reach USD 26.01 Billion By 2023

Antimicrobial Additives Market Growth Accelerated By Rising Demand From End-Use Industries